News

Researchers found patients treated with risankizumab had higher rates of skin clearance and greater improvement than those treated with deucravacitinib.

The FDA recently approved Yesintek for treating psoriasis, psoriatic arthritis, and IBD, with a 2025 launch expected.

Promising new data was released along with a timeline of upcoming studies evaluating potential combination therapies for atopic dermatitis.

Explore key insights and innovations in vitiligo from 2024, from treatment advances to patient-focused strategies.

LOV has unique clinical traits, epidemiology, and treatment responses compared to early-onset vitiligo, underscoring the need for a tailored management approach.

Treatment with delgocitinib led to a significant decrease in the expression of inflammatory markers that were elevated in severe cases compared with mild cases at baseline.

Regenerative methods such as cell therapy and platelet-rich plasma showed promising results in patient repigmentation.

If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.

Read more about acne treatment tips shared at the 2024 SDPA Fall Conference by experts such as Shanna Miranti, MPAS, PA-C, and Hilary Baldwin, MD.

A clinical trial and laboratory study assessed skin’s hydration, antioxidation, and wrinkle presence after treatment with cacao.

Dermatology Times asked our readers to share what conferences they are looking forward to in the fourth quarter of 2024.

Ahead of 2025, Dermatology Times wants to know what conferences and meetings you plan to attend in early 2024. Share your thoughts with us by December 10.

Learn more about the in-depth topics covered in the November 2024 CHE digital supplement of Dermatology Times.

Hawkes highlighted how second-generation TYK2 inhibitors improve upon earlier oral therapies with greater efficacy and selectivity.

Dermatology Times is looking back on the top stories in dermatology from the month of November.

Dermatology Times is recapping our top expert interviews from the month of November.

Data from Galderma's OLYMPIA 1 trial was recently published in JAMA Dermatology.

Learn more about the in-depth topics covered in the November 2024 AD and Vitiligo supplement of Dermatology Times.

Hawkes highlighted the intersection of oncology and dermatology, focusing on immune checkpoint inhibitors and their cutaneous adverse events.

A message of gratitude to the dermatology community for 45 years of collaboration, insights, and advancing care worldwide.

Learn more about the in-depth topics covered in the November 2024 print issue of Dermatology Times.

Patients treated with radiofrequency microneedling and Cysteamine cream saw significant improvement in melasma severity and skin texture.

Unlike previous therapies, bimekizumab has shown continued efficacy at 48 and 96 weeks, offering long-term benefits to HS patients.

This study demonstrates the use of AI-driven image analysis, leveraging the ScarletredVision app and machine learning, to diagnose and assess onychomycosis.

Plant-based compounds are being explored for their antioxidant and anti-inflammatory benefits in skin care.

Patients in 8 case studies saw notable improvements in post-traumatic, post-operative, and burn-related scars.

Older adults with higher genetic risk for HS show increased risks for coronary artery disease and diabetes, according to UK Biobank data.

The pivotal BE HEARD trials demonstrated bimekizumab’s efficacy, showing meaningful improvements over placebo in HS patients.

Many dermatologists want to donate to charity while maximizing tax benefits, and certain tools can help achieve this.